‘Pre-Connecting’ on API issues, regulatory questions, emerging markets and biosimilars
What did you miss? Read an expert analysis of top, need-to-know information presented at this year’s CPHI Worldwide Pre-Connect Congress.
The day before CPHI Worldwide began in Frankfurt, Germany, this past October, several hundred people gathered for the day-long Pre-Connect Congress to learn, network, and gather insights on the pressing topics that impact pharma growth and development year-round.
In a new article, industry expert and CPHI Worldwide presenter Kate Kuhrt of Clarivate Analytics highlights some of the top, need-to-know information presented at this year’s Pre-Connect Congress – including trends in API sourcing and contract manufacturing, biosimilars, new regulations and regulatory compliance, and developments in emerging markets.
Her overview summarizes findings from key experts, including Pre-Connect keynote speaker Tae Han Kim, president and CEO of Samsung BioLogics, and Alan Sheppard, principal, global generics, thought leadership at IQVIA, formerly QuintilesIMS.
Kuhrt details findings from four Pre-Connect sessions:
• “Biologics: Growing industry with growing uncertainty” (CEO Keynote)
• “API sourcing and manufacturing update”
• “The future of generics”
• “Biosimilar update in the U.S. and Europe”
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance